Credit Suisse’s Praxis Precision Medicines PRAX Stock Holding History

Credit Suisse’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	-$5	–	3611
2022 Q4	–	Sell	-1,032	Closed	-$32.2K	–	3823
2022 Q3	$35K	Buy	1,032 +12	+1%	+$598	﹤0.01%	3563
2022 Q2	$37K	Sell	1,020 -18	-2%	-$1.92K	﹤0.01%	3658
2022 Q1	$159K	Sell	1,038 -64	-6%	-$13.1K	﹤0.01%	3422
2021 Q4	$327K	Buy	1,102 +223	+25%	+$65.4K	﹤0.01%	4087
2021 Q3	$243K	Buy	879 +157	+22%	+$42.6K	﹤0.01%	4164
2021 Q2	$197K	Buy	+722	New	+$259K	﹤0.01%	4285

Other funds holding PRAX

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Credit Suisse's PRAX Position: Q1 2023 in Review

Credit Suisse held its Praxis Precision Medicines (PRAX) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3611.

Credit Suisse first reported a position in PRAX in Q2 2021 and has held it in 6 quarters since. The position peaked at $327K in Q4 2021. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

Credit Suisse held 0 shares of Praxis Precision Medicines worth $0 as of Q1 2023.
Credit Suisse left its Praxis Precision Medicines share count unchanged in Q1 2023.
Praxis Precision Medicines made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3611 holding.
Credit Suisse first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 6 quarters since.
Credit Suisse's Praxis Precision Medicines position peaked at $327K in Q4 2021.
86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.